In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will acquire treatment right up until sickness progression or maybe the contributors are unable to tolerate the study drugs. - "Our study discovered the vital position from the KLF16/MYC regulatory https://clinicaleffectivenessofab80235.loginblogin.com/38983142/5-easy-facts-about-is-abbv-744-effective-for-hematologic-cancers-described